View Document Preview and Link Document Date: 2010-09-08 05:47:02 Open Document File Size: 59,12 KB Share Result on Facebook
City Munich / / Company Octapharma / Celestial Biologicals Ltd / vWD / Zymogenetics / Biogen Idec / Zymogenetic / Baxter / Talecris / Omri Laboratories / Bayer Schering Pharma / GE Healthcare / Grifols / Novo Nordisk / Intas Biopharmaceuticals Ltd / Bayer Corp / / Continent North America / Europe / / Country Russia / United States / Israel / India / / Currency USD / / / Event Business Partnership / FDA Phase / IPO / / Facility Plasma Fractionation facility / / IndustryTerm plasma products / appropriate technology / imported plasma products / biotechnology / delivery technology / technology license / recombinant technology basis / main pharmaceutical markets / liposome technology / manufacturing process / individual coagulation factor products / plasma/albumin-free manufacturing platform technology / avian transgenic technology / manufacturing / transgenic technology / / MedicalCondition clinically significant disease / common congenital coagulation disorder / afibrinogenemia / Compound Company Product Category RNA Indication Hemophilia A / Although von Willebrand disease / von Willebrand disease / disorders / Other Coagulation Factors Hemophilia A / / NaturalFeature Compound Technology Kogenate Lipo BAY / / Organization Central Drugs Standard Control Organization / La Merie Business Intelligence / FDA / DGHS / / Person Jordi Ferran / / / Position Executive / / Product FS / US FDA / / ProvinceOrState Indiana / / Region south Asia / / Technology biotechnology / Delivery technology / NecLip technology / pharmacokinetics / Biopharmaceuticals / Recoly technology / transgenic technology / avian transgenic technology / liposome technology / Business Intelligence / plasma/albumin-free manufacturing platform technology / / SocialTag 
Microsoft Word - Full Report Coagulation Factors September 2010